Statement re Share Price Movement

(AIM: SAR)   9 February 2011


                              SAREUM HOLDINGS PLC
                          ("Sareum" or the "Company")

                       Statement re Share Price Movement

Sareum  (AIM: SAR), the specialist cancer drug discovery business, has noted the
recent  significant  rise  in  the  Company's  share price, the volume of shares
traded  in  the  last  two  trading  sessions  and  the bulletin board and press
comments  following the announcement  made on 7 February  2011 with the headline
"Research Update: Positive Leukaemia Model Study".
The  Company  can  confirm  that  it  is  not  currently  in  advanced stages of
discussion with a potential licencing partner and there can be no certainty that
the  announcement  of  these  results  will  lead to a licencing agreement being
entered into.

The  Company can  confirm that  the results  of the  study have, in the ordinary
course  of business, been  sent to potential  licencing partners and the Company
will be engaging with these partners to determine their interest in the data.

 Sareum Holdings plc

 Tim Mitchell                 01223 497 700



 Merchant Securities Limited (Nomad)

 Simon Clements/Bidhi Bhoma   020 7628 2200



 Hybridan LLP (Broker)

 Claire Noyce                 020 7947 4350


Notes for editors:

About Sareum Holdings plc
Sareum  is  a  drug  discovery  company,  headquartered in Cambridge UK, that is
focused  on  producing  targeted  small  molecule  therapeutics to address unmet
medical  needs, primarily  in cancer.  Sareum aims  to successfully deliver drug
candidates  for licensing to  pharmaceutical and biotechnology  companies at the
pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration
with  The Institute of  Cancer Research and  Cancer Research Technology Limited.
Novel  chemical  compounds  developed  by  the  collaboration have been shown to
increase  the  effectiveness  of  current  cancer therapeutics in in-vivo cancer
models.

SKIL®  (Sareum Kinase Inhibitor  Library) is Sareum's  drug discovery technology
platform  that has so far produced  the Company's Aurora+FLT3, Aurora+ALK VEGFR-
3, FLT3  & TYK2 kinase cancer and  auto-immune disease research programmes. SKIL
can also generate drug research programmes against other kinase targets.

Sareum  Holdings  plc  joined  the  AIM  market  of the London Stock Exchange in
October  2004, trading under  the symbol  SAR.  For  further information, please
visit www.sareum.co.uk







This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE

[HUG#1487061]